Analysis of HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention

November 5, 2024
Several green spheres bound together in a line and budding from irregular matter.

Colorized transmission electron micrograph of multiple HIV-1 virus particles (green) budding from a cell projection from an H9 cell (burgundy). Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland.

Credit: NIAID

An analysis of HIV Prevention Trials Network studies of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis (CAB-LA PrEP) showed that some people who acquired HIV while taking CAB-LA had lower HIV DNA levels than those on tenofovir-based PrEP. 

Read more in the publication, HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 08.

Content last reviewed on